2 results
Approved WMOCompleted
To 1) clinically validate the novel PET-tracer [18F]AV1451 for tau pathology as a diagnostic and prognostic marker in tauopathies, 2) to examine the (change in) (regional) binding of [18F]AV1451 across tauopathies, and the relationships between (…
Approved WMOCompleted
Primary ObjectivesDose Escalation Phase* To determine the maximum tolerated dose (MTD) of multiple ERY974 dosing schedules, including fixed dose schedules and an individual dose titration schedule, in patients with locally advanced or metastatic…